Please use this identifier to cite or link to this item:
http://hdl.handle.net/1942/33080
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Vanassche, T. | - |
dc.contributor.author | Engelen, M. M. | - |
dc.contributor.author | Van Thillo, Q. | - |
dc.contributor.author | Wauters, J. | - |
dc.contributor.author | Gunst, J. | - |
dc.contributor.author | Wouters, C. | - |
dc.contributor.author | Vandenbriele, C. | - |
dc.contributor.author | Rex, S. | - |
dc.contributor.author | LIESENBORGHS, L. | - |
dc.contributor.author | Wilmer, A. | - |
dc.contributor.author | Meersseman, P. | - |
dc.contributor.author | Van den Berghe, G. | - |
dc.contributor.author | Dauwe, D. | - |
dc.contributor.author | VERBEKE, Geert | - |
dc.contributor.author | THOMEER, Michiel | - |
dc.contributor.author | Fivez, T. | - |
dc.contributor.author | MESOTTEN, Dieter | - |
dc.contributor.author | RUTTENS, David | - |
dc.contributor.author | Heytens, L. | - |
dc.contributor.author | Dapper, I. | - |
dc.contributor.author | Tuyls, S. | - |
dc.contributor.author | De Tavernier, B. | - |
dc.contributor.author | Verhamme, P. | - |
dc.date.accessioned | 2021-01-13T12:13:22Z | - |
dc.date.available | 2021-01-13T12:13:22Z | - |
dc.date.issued | 2020 | - |
dc.date.submitted | 2021-01-12T13:49:09Z | - |
dc.identifier.citation | Trials, 21 (1) (Art N° 1005) | - |
dc.identifier.uri | http://hdl.handle.net/1942/33080 | - |
dc.description.abstract | Background: The peak of the global COVID-19 pandemic has not yet been reached, and many countries face the prospect of a second wave of infections before effective vaccinations will be available. After an initial phase of viral replication, some patients develop a second illness phase in which the host thrombotic and inflammatory responses seem to drive complications. Severe COVID-19 disease is linked to high mortality, hyperinflammation, and a remarkably high incidence of thrombotic events. We hypothesize a crucial pathophysiological role for the contact pathway of coagulation and the kallikrein-bradykinin pathway. Therefore, drugs that modulate this excessive thromboinflammatory response should be investigated in severe COVID-19. | - |
dc.description.sponsorship | This study is funded by Life Sciences Research Partners (LSRP), Research Foundation - Flanders (FWO) project G0G4720N, and the COVID-19 fund of the KU Leuven. The authors are fully responsible for the design of the study; for the collection, analysis, and interpretation of the data; and for the writing of the manuscript. The sponsor (University Hospitals Leuven) is represented in the steering committee and has insight in the study design and the collection and interpretation of data. The study is financed by academic research grants by the Internal Research Grants of the University Hospitals Leuven (KOOR) and a National Research Grant from the Research Foundation - Flanders (FWO). These funding bodies have no role in the design of the study; the collection, analysis, and interpretation of the data; or the writing of the manuscript. | - |
dc.language.iso | en | - |
dc.publisher | BMC | - |
dc.rights | The Author(s). 2020, corrected publication 2020. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. | - |
dc.subject.other | COVID-19 | - |
dc.subject.other | SARS-CoV-2 | - |
dc.subject.other | Low molecular weight heparins | - |
dc.subject.other | Aprotinin | - |
dc.subject.other | Anakinra | - |
dc.subject.other | Thromboinflammatory response | - |
dc.subject.other | Thrombosis | - |
dc.subject.other | Inflammation | - |
dc.title | A randomized, open-label, adaptive, proof-of-concept clinical trial of modulation of host thromboinflammatory response in patients with COVID-19: the DAWn-Antico study | - |
dc.type | Journal Contribution | - |
dc.identifier.issue | 1 | - |
dc.identifier.volume | 21 | - |
local.bibliographicCitation.jcat | A1 | - |
local.publisher.place | CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND | - |
local.type.refereed | Refereed | - |
local.type.specified | Article | - |
local.bibliographicCitation.artnr | 1005 | - |
dc.identifier.doi | 10.1186/s13063-020-04878-y | - |
dc.identifier.pmid | 33298149 | - |
dc.identifier.isi | WOS:000600118700001 | - |
local.provider.type | CrossRef | - |
local.uhasselt.uhpub | yes | - |
local.uhasselt.international | no | - |
item.fulltext | With Fulltext | - |
item.contributor | Vanassche, T. | - |
item.contributor | Engelen, M. M. | - |
item.contributor | Van Thillo, Q. | - |
item.contributor | Wauters, J. | - |
item.contributor | Gunst, J. | - |
item.contributor | Wouters, C. | - |
item.contributor | Vandenbriele, C. | - |
item.contributor | Rex, S. | - |
item.contributor | LIESENBORGHS, L. | - |
item.contributor | Wilmer, A. | - |
item.contributor | Meersseman, P. | - |
item.contributor | Van den Berghe, G. | - |
item.contributor | Dauwe, D. | - |
item.contributor | VERBEKE, Geert | - |
item.contributor | THOMEER, Michiel | - |
item.contributor | Fivez, T. | - |
item.contributor | MESOTTEN, Dieter | - |
item.contributor | RUTTENS, David | - |
item.contributor | Heytens, L. | - |
item.contributor | Dapper, I. | - |
item.contributor | Tuyls, S. | - |
item.contributor | De Tavernier, B. | - |
item.contributor | Verhamme, P. | - |
item.accessRights | Open Access | - |
item.validation | ecoom 2022 | - |
item.fullcitation | Vanassche, T.; Engelen, M. M.; Van Thillo, Q.; Wauters, J.; Gunst, J.; Wouters, C.; Vandenbriele, C.; Rex, S.; LIESENBORGHS, L.; Wilmer, A.; Meersseman, P.; Van den Berghe, G.; Dauwe, D.; VERBEKE, Geert; THOMEER, Michiel; Fivez, T.; MESOTTEN, Dieter; RUTTENS, David; Heytens, L.; Dapper, I.; Tuyls, S.; De Tavernier, B. & Verhamme, P. (2020) A randomized, open-label, adaptive, proof-of-concept clinical trial of modulation of host thromboinflammatory response in patients with COVID-19: the DAWn-Antico study. In: Trials, 21 (1) (Art N° 1005). | - |
crisitem.journal.eissn | 1745-6215 | - |
Appears in Collections: | Research publications |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
s13063-020-04878-y.pdf | Published version | 1.34 MB | Adobe PDF | View/Open |
WEB OF SCIENCETM
Citations
12
checked on Apr 22, 2024
Page view(s)
32
checked on Jul 20, 2022
Download(s)
12
checked on Jul 20, 2022
Google ScholarTM
Check
Altmetric
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.